BioSpace News Archive

CNS’ lead drug candidate Berubicin is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer

Dr. Vladimir Zelenko and team announced that a retrospective study analyzing his patient data was accepted for publication after a rigorous peer review process.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology, announced today that it will report its third quarter 2020 financial results and provide a business update on Thursday, November 12 th , 2020 before the open of the U.S. financial markets.

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with more than 80,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexi

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its third quarter financial results and other business updates on November 12, 2020. The company will host a conference call at 8:30 a.m.

Nucleix’s Lung EpiCheck ® Liquid Biopsy Test Detects 85% of Early Stage Lung Cancers in High-Risk Smokers, Study Published in European Respiratory Journal Cost-effective blood test, combined with patient clinical factors, significantly improves AUC to 94%

Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA ® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout -- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the KRYSTEXXA patient experience --

Use of coronary CTA instead of stress tests alone results in increased early initiation of preventative therapy and 41% reduction in cardiac death and myocardial infarction

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, will host a conference call at 8:00 a.m. ET on Thursday, November 5, 2020, to discuss financial results for the quarter ended September 30, 2020, and provide a corporate update. The dial-in numbe

-- Presentations Detail Twist’s Methylation Solution, a Cost-Effective Alternative to Single Nucleotide Polymorphism (SNP) Microarray Technology and Data on the Infectious Disease Product Line --